![media](https://mms.businesswire.com/media/20240828277262/en/2159786/3/enGene_Logo.jpg)
BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in
Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!
Easy Branches
34/17 Moo 3 Chao fah west Road, Phuket, Thailand, PhuketCall: 076 367 766
info@easybranches.comBOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in